Tff Pharmaceuticals Inc [TFFP] stock Resumed by H.C. Wainwright analyst, price target now $22

MU Stock

Tff Pharmaceuticals Inc [NASDAQ: TFFP] traded at a high on Thursday, posting a 8.74 gain after which it closed the day’ session at $0.40.

The results of the trading session contributed to over 29987660 shares changing hands. Over the past one week, the price volatility of Tff Pharmaceuticals Inc stands at 34.16% while the volatility over the past one month is 21.61%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The market cap for TFFP stock reached $1.37 million, with 3.47 million shares outstanding and 3.10 million shares in the current float. Compared to the average trading volume of 293.18K shares, TFFP reached a trading volume of 29987660 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Tff Pharmaceuticals Inc [TFFP]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TFFP shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TFFP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Tff Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 19, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on February 08, 2021, representing the official price target for Tff Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $36, while B. Riley Securities analysts kept a Buy rating on TFFP stock. On August 17, 2020, analysts increased their price target for TFFP shares from 12 to 18.

The Average True Range (ATR) for Tff Pharmaceuticals Inc is set at 0.33 The Price to Book ratio for the last quarter was 0.22, with the Price to Cash per share for the same quarter was set at 1.27.

How has TFFP stock performed recently?

Tff Pharmaceuticals Inc [TFFP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -78.13. With this latest performance, TFFP shares dropped by -82.79% in over the last four-week period, additionally sinking by -82.33% over the last 6 months – not to mention a drop of -94.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TFFP stock in for the last two-week period is set at 24.25, with the RSI for the last a single of trading hit 18.00, and the three-weeks RSI is set at 29.02 for Tff Pharmaceuticals Inc [TFFP]. The present Moving Average for the last 50 days of trading for this stock 1.9560, while it was recorded at 0.8832 for the last single week of trading, and 3.1168 for the last 200 days.

Tff Pharmaceuticals Inc [TFFP]: Deeper insight into the fundamentals

Tff Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.63 and a Current Ratio set at 1.63.

Insider trade positions for Tff Pharmaceuticals Inc [TFFP]

There are presently around $24.37%, or 25.21%% of TFFP stock, in the hands of institutional investors.

Most Popular